rare disease drugs
Scope
Date
~
-
Bio & Pharma
JW Pharma to put AI into new drug ingredient development
South Korea's drug developer JW Pharmaceutical is expanding the scope of its artificial intelligence (AI) uses from new drug research to the develop...
Jan 30, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea, Japan compete in gastroesophageal reflux drug market
South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical pr...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Bridge Biotherapeutics, Pinotbio develop lung cancer treatment
South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N to introduce biosimilars for bone disease treatment from Spain
South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Inventage Lab launches clinical trials for addiction treatment in Australia
South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics C...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N's K-CAB to get insurance benefits in China
South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
ST Pharm exports $14.6 mn worth of drug ingredients to Europe
ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma's Sanfilippo treatment eligible for FDA priority review
GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture special...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong accelerates investment in CDMO business
Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Biomedics gets approval for Parkinson's disease clinical trials
South Korea's biomedicine firm S.Biomedics said on Friday that it has won approval from the Ministry of Food and Drug Safety for phase 1 and 2a clin...
Jan 13, 2023 (Gmt+09:00)
-
Bio & Pharma
JVM to sell fully automated drug inspection machines in US
Hanmi Pharmaceutical Co. said on Monday that it had signed an agreement with Euclid Medical Products, a company specializing in manufacturing drug d...
Jan 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong, Onchorus to undertake research on mRNA anticancer drugs
Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals introduces Tiglutik, treatment for Lou Gehrig's disease
SK Chemicals said on Monday that it is strengthening its portfolio of neurological diseases by introducing Tiglutik (riluzole), Lou Gehrig's disease...
Jan 02, 2023 (Gmt+09:00)
-
Supply chain
South Korea to double stockpiles of rare-earth minerals
South Korea's Ministry of Trade, Industry and Energy said on Friday it will double the government's stockpiles of rare-earth minerals and halve thei...
Dec 30, 2022 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, Neurolive to jointly develop new antidepressant drug
South Korea's drug company Daewoong Pharmaceutical said on Wednesday that it has signed an agreement with biopharmaceutical venture Neurorive to joi...
Dec 28, 2022 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ applies to FDA for trials of immuno-anticancer drug candidate
CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 ...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Dong-A ST incorporates NeuroBo as subsidiary
Dong-A ST said on Friday that it would acquire American drug company NeuroBo Pharmaceuticals as a subsidiary.NeuroBo, located in Boston, is a Nasdaq...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biopharmaceutical sector to see brisk M&As in H1, 2023
An expert says the first half of next year will see the start of brisk M&As in biopharmaceuticals targeting strategic investors.Pyeon Jae-seong,...
Dec 21, 2022 (Gmt+09:00)
-
Bio & Pharma
Bigsome Bio signs tech transfer agreement with university
Bigsome Bio, a subsidiary of Lotte Chilsung Beverage, has begun research on functional materials for respiratory health.The company said on Friday t...
Dec 20, 2022 (Gmt+09:00)
-
Artificial intelligence
Syntekabio launches new drug development platform STB Cloud in US
Syntekabio,Inc., a South Korean artificial intelligence (AI) drug development company, said on Monday it has launched its cloud-based AI drug develo...
Dec 19, 2022 (Gmt+09:00)
-
Companies
SK Materials, Arencibia ink MOU on noble gas recycling
SK Materials Airplus Co. announced on Monday that it signed an MOU with US-based Arencibia to prepare to enter the noble gas recycling business.&n...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem in $95.5 million drug out-licensing deal with China’s Innovent
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., and China’s biotech company Innovent Biologics have entered into a strategi...
Dec 15, 2022 (Gmt+09:00)
-
Bio & Pharma
Daewoong submits new drug applications for Fexuclue in 10 countries
South Korea's leading drug company Daewoong Pharmaceutical is accelerating its global expansion efforts for its 34th domestically developed drug Fex...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...
Dec 14, 2022 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand